Gross Profit Analysis: Comparing Incyte Corporation and Grifols, S.A.

Incyte's growth outpaces Grifols in gross profit from 2014-2023.

__timestampGrifols, S.A.Incyte Corporation
Wednesday, January 1, 20141699214000508491000
Thursday, January 1, 20151930998000726779000
Friday, January 1, 201619122910001047532000
Sunday, January 1, 201721520110001456737000
Monday, January 1, 201820495600001787760000
Tuesday, January 1, 201923412320002044510000
Wednesday, January 1, 202022551650002535374000
Friday, January 1, 202119625960002835276000
Saturday, January 1, 202222315300003187638000
Sunday, January 1, 202323227010003440649000
Monday, January 1, 20243929149000
Loading chart...

Infusing magic into the data realm

Gross Profit Trends: Incyte Corporation vs. Grifols, S.A.

In the ever-evolving pharmaceutical industry, understanding financial performance is crucial. This analysis compares the gross profit trends of Incyte Corporation and Grifols, S.A. from 2014 to 2023. Over this period, Incyte Corporation has shown a remarkable growth trajectory, with its gross profit increasing by approximately 577%, from $508 million in 2014 to $3.44 billion in 2023. This growth highlights Incyte's strategic advancements and market expansion.

Conversely, Grifols, S.A. has maintained a steady performance, with a 37% increase in gross profit, rising from $1.70 billion in 2014 to $2.32 billion in 2023. This stability underscores Grifols' consistent market presence and operational efficiency. The data reveals a compelling narrative of growth and stability, offering valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025